{"DataElement":{"publicId":"2866464","version":"1","preferredName":"Southwest Oncology Group Patient Registration Bevacizumab Eligibility Determination Status","preferredDefinition":"the status of whether a Southwest Oncology Group (an NCI-sponsored cooperative group adult cancer clinical trials organization) subject is suitable for enrollment in a study according to bevacizumab-specific protocol criteria and procedures.","longName":"SWOG_PT_R_B_ELG_STAT","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2866448","version":"1","preferredName":"Southwest Oncology Group Patient Registration Bevacizumab Eligibility Determination","preferredDefinition":"information relating to bevacizumab (a monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor) and the act of determining if a Southwest Oncology Group (an NCI-sponsored cooperative group adult cancer clinical trials organization) subject is suitable for enrollment in a study according to specific protocol criteria and procedures.","longName":"SWOG_PT_REG_BEV_ELIG","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2436359","version":"1","preferredName":"Southwest Oncology Group Patient","preferredDefinition":"The Southwest Oncology Group (SWOG) is an NCI-sponsored cooperative group, an adult cancer clinical trials organization, one of the largest in the world. The group was established in 1956 and is headquartered in San Antonio, TX. Its network consists of almost 4,000 of the physicians at 283 institutions throughout the US and Canada. The major goal of the SWOG since 1990 has been to enroll more women and minority patients in cancer treatment and control research trials.:A person who requires medical care.","longName":"C25699:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Southwest Oncology Group","conceptCode":"C25699","definition":"An NCI-sponsored cooperative group, an adult cancer clinical trials organization, one of the largest in the world. The group was established in 1956 and is headquartered in San Antonio, TX. Its network consists of almost 4,000 of the physicians at 283 institutions throughout the US and Canada. The major goal of the SWOG since 1990 has been to enroll more women and minority patients in cancer treatment and control research trials.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0781A8FE-557E-0C0C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-12-12","modifiedBy":"ONEDATA","dateModified":"2005-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2866446","version":"1","preferredName":"Registration Bevacizumab Eligibility Determination","preferredDefinition":"The act of listing or recording officially; officially qualified or enrolled.:A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.:Criteria to determine eligibility of patients for medical care programs and services.","longName":"C25646:C2039:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Registration","conceptCode":"C25646","definition":"The act of listing or recording officially; officially qualified or enrolled.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68C72403-E713-1C25-E040-BB89AD4376F5","latestVersionIndicator":"Yes","beginDate":"2009-04-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-04-30","modifiedBy":"ONEDATA","dateModified":"2009-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68C72403-E724-1C25-E040-BB89AD4376F5","latestVersionIndicator":"Yes","beginDate":"2009-04-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-04-30","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2866458","version":"1","preferredName":"Southwest Oncology Group Bevacizumab Eligibility Status","preferredDefinition":"the status of whether a Southwest Oncology Group (an NCI-sponsored cooperative group adult cancer clinical trials organization) subject is suitable for enrollment in a study according to bevacizumab-specific protocol criteria and procedures.","longName":"SWOG_BEV_ELIG_STAT","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"2","valueDescription":"Bevacizumab-appropriate","ValueMeaning":{"publicId":"2866460","version":"1","preferredName":"Bevacizumab-appropriate","longName":"2866460","preferredDefinition":"Bevacizumab-appropriate","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68C76989-4391-666B-E040-BB89AD437F1C","latestVersionIndicator":"Yes","beginDate":"2009-04-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84C14068-8F65-5E43-E040-BB89AD435272","beginDate":"2009-04-30","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-04-21","modifiedBy":"ONEDATA","dateModified":"2010-04-21","deletedIndicator":"No"},{"value":"1","valueDescription":"Bevacizumab-inappropriate","ValueMeaning":{"publicId":"2866459","version":"1","preferredName":"Bevacizumab-inappropriate","longName":"2866459","preferredDefinition":"Bevacizumab-inappropriate","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68C76989-436E-666B-E040-BB89AD437F1C","latestVersionIndicator":"Yes","beginDate":"2009-04-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84C14068-8F79-5E43-E040-BB89AD435272","beginDate":"2009-04-30","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-04-21","modifiedBy":"ONEDATA","dateModified":"2010-04-21","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"68C76989-435A-666B-E040-BB89AD437F1C","latestVersionIndicator":"Yes","beginDate":"2009-04-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-04-30","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811832","version":"1","longName":"Lung","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Based on the definition in se","type":"Preferred Question Text","description":"Based on the definition in section 6.1 of the protocol, classify the patient as bevacizumab-appropriate or bevacizumab-inappropriate","url":null,"context":"CTEP"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"68C76989-441C-666B-E040-BB89AD437F1C","latestVersionIndicator":"Yes","beginDate":"2009-04-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-04-30","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}